{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:52:26Z","timestamp":1760151146289,"version":"build-2065373602"},"reference-count":183,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007076","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG24930"],"award-info":[{"award-number":["IG24930"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Aberrant signaling in myeloproliferative neoplasms may arise from alterations in genes coding for signal transduction proteins or epigenetic regulators. Both mutated and normal cells cooperate, altering fragile balances in bone marrow niches and fueling persistent inflammation through paracrine or systemic signals. Despite the hopes placed in targeted therapies, myeloid proliferative neoplasms remain incurable diseases in patients not eligible for stem cell transplantation. Due to the emergence of drug resistance, patient management is often very difficult in the long term. Unexpected connections among signal transduction pathways highlighted in neoplastic cells suggest new strategies to overcome neoplastic cell adaptation.<\/jats:p>","DOI":"10.3390\/cancers14040972","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T22:43:22Z","timestamp":1644965002000},"page":"972","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-9189","authenticated-orcid":false,"given":"Maria Teresa","family":"Bochicchio","sequence":"first","affiliation":[{"name":"Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3641-3643","authenticated-orcid":false,"given":"Valeria","family":"Di Battista","sequence":"additional","affiliation":[{"name":"Hematology Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Poggio","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6263-6800","authenticated-orcid":false,"given":"Giovanna","family":"Carr\u00e0","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Torino, 10043 Orbassano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8407-2903","authenticated-orcid":false,"given":"Alessandro","family":"Morotti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Torino, 10043 Orbassano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2327-6846","authenticated-orcid":false,"given":"Mara","family":"Brancaccio","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-5311","authenticated-orcid":false,"given":"Alessandro","family":"Lucchesi","sequence":"additional","affiliation":[{"name":"Hematology Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d, 47014 Meldola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Pikman, Y., Lee, B.H., Mercher, T., McDowell, E., Ebert, B.L., Gozo, M., Cuker, A., Wernig, G., Moore, S., and Galinsky, I. (2006). MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030270"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13148-011-0050-6","article-title":"Epigenetic abnormalities in myeloproliferative neoplasms: A target for novel therapeutic strategies","volume":"2","author":"Mascarenhas","year":"2011","journal-title":"Clin. Epigenet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3324\/haematol.2010.029678","article-title":"Extent of hematopoietic involvement by TET2 mutations in JAK2V(6)(1)(7)F polycythemia vera","volume":"96","author":"Swierczek","year":"2011","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2012-10-464248","article-title":"Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms","volume":"121","author":"Kennedy","year":"2013","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajh.25303","article-title":"Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management","volume":"94","author":"Tefferi","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: Result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: An ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"664305","DOI":"10.3389\/fcell.2021.664305","article-title":"Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation","volume":"9","author":"Li","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Di Battista, V., Bochicchio, M.T., Giordano, G., Napolitano, M., and Lucchesi, A. (2021). Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020561"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.exphem.2015.06.007","article-title":"Pathogenesis of myeloproliferative neoplasms","volume":"43","author":"Skoda","year":"2015","journal-title":"Exp. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2014.113845","article-title":"Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms","volume":"102","author":"Grinfeld","year":"2017","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/leu.2013.302","article-title":"Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms","volume":"28","author":"Tenedini","year":"2014","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","article-title":"Prognostic impact of RAS-pathway mutations in patients with myelofibrosis","volume":"34","author":"Santos","year":"2020","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"ra122","DOI":"10.1126\/scisignal.2005301","article-title":"RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis","volume":"7","author":"Winter","year":"2014","journal-title":"Sci. Signal."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hautin, M., Mornet, C., Chauveau, A., Bernard, D.G., Corcos, L., and Lippert, E. (2020). Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues. Cancers, 12.","DOI":"10.3390\/cancers12082216"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.mayocp.2017.06.002","article-title":"Genetic Risk Assessment in Myeloproliferative Neoplasms","volume":"92","author":"Tefferi","year":"2017","journal-title":"Mayo Clinic Proc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Stuckey, R., and Gomez-Casares, M.T. (2021). Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22095042"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.blre.2016.11.004","article-title":"Modeling myeloproliferative neoplasms: From mutations to mouse models and back again","volume":"31","author":"Morotti","year":"2017","journal-title":"Blood Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1242\/dmm.006817","article-title":"Mouse models of myeloproliferative neoplasms: JAK of all grades","volume":"4","author":"Li","year":"2011","journal-title":"Dis. Models Mech."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.molcel.2006.12.008","article-title":"An acetylation site in the middle domain of Hsp90 regulates chaperone function","volume":"25","author":"Scroggins","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1097\/HS9.0000000000000516","article-title":"Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms","volume":"5","author":"Brkic","year":"2021","journal-title":"HemaSphere"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.hoc.2017.04.003","article-title":"Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms","volume":"31","author":"Meyer","year":"2017","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): A randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-alpha2 combination therapy for patients with polycythemia vera or myelofibrosis: A phase II study","volume":"105","author":"Sorensen","year":"2020","journal-title":"Haematologica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2019-129245","article-title":"Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician\u2019s Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000\/mL)","volume":"134","author":"Harrison","year":"2019","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Marit, M.R., Chohan, M., Matthew, N., Huang, K., Kuntz, D.A., Rose, D.R., and Barber, D.L. (2012). Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0043437"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2011.255","article-title":"Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms","volume":"26","author":"Deshpande","year":"2012","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2013-05-504555","article-title":"Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors","volume":"123","author":"Marty","year":"2014","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s12185-013-1353-5","article-title":"Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms","volume":"97","author":"Bhagwat","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41698-021-00215-x","article-title":"Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia","volume":"5","author":"Downes","year":"2021","journal-title":"NPJ Precis. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/asheducation-2014.1.287","article-title":"The evolving genomic landscape of myeloproliferative neoplasms","volume":"2014","author":"Nangalia","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci. Publ. Protein Soc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000Research"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging Topical and Systemic JAK Inhibitors in Dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: A leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4161\/jkst.20006","article-title":"STAT signaling in the pathogenesis and treatment of myeloid malignancies","volume":"1","author":"Nelson","year":"2012","journal-title":"Jak-Stat"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Guijarro-Hernandez, A., and Vizmanos, J.L. (2021). A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms. Cancers, 13.","DOI":"10.3390\/cancers13050984"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.celrep.2019.09.035","article-title":"Signal Integration and Transcriptional Regulation of the Inflammatory Response Mediated by the GM-\/M-CSF Signaling Axis in Human Monocytes","volume":"29","author":"Rodriguez","year":"2019","journal-title":"Cell Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrrheum.2015.161","article-title":"Targeting GM-CSF in inflammatory diseases","volume":"12","author":"Wicks","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Comoglio, F., Park, H.J., Schoenfelder, S., Barozzi, I., Bode, D., Fraser, P., and Green, A.R. (2018). Thrombopoietin signaling to chromatin elicits rapid and pervasive epigenome remodeling within poised chromatin architectures. Genome Res.","DOI":"10.1101\/163113"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature08448","article-title":"JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin","volume":"461","author":"Dawson","year":"2009","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood-2011-02-336479","article-title":"Confocal imaging studies cast doubt on nuclear localization of JAK2V617F","volume":"118","author":"Girodon","year":"2011","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"35486","DOI":"10.1074\/jbc.M404202200","article-title":"Janus kinase (Jak) subcellular localization revisited: The exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase","volume":"279","author":"Behrmann","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"11766","DOI":"10.1073\/pnas.1805662115","article-title":"KDM3A histone demethylase functions as an essential factor for activation of JAK2-STAT3 signaling pathway","volume":"115","author":"Kim","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"32971","DOI":"10.1074\/jbc.M105412200","article-title":"PRMT5 (Janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins","volume":"276","author":"Branscombe","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/ncb1802","article-title":"Arginine methylation regulates the p53 response","volume":"10","author":"Jansson","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1073\/pnas.1401180111","article-title":"Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition","volume":"111","author":"Lupardus","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nsmb.2849","article-title":"Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase","volume":"21","author":"Shan","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.aaw3242","article-title":"Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations","volume":"367","author":"Wilmes","year":"2020","journal-title":"Science"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1182\/blood-2010-08-302265","article-title":"Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia","volume":"116","author":"Rinaldi","year":"2010","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1073\/pnas.95.7.3890","article-title":"The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis","volume":"95","author":"Yamada","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2019000095","article-title":"LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis","volume":"134","author":"Morishima","year":"2019","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2010.12.020","article-title":"JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation","volume":"19","author":"Liu","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/14712598.2014.867323","article-title":"Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia","volume":"14","author":"Morotti","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI98785","article-title":"Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms","volume":"129","author":"Stivala","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3324\/haematol.2020.262691","article-title":"Persistence of myelofibrosis treated with ruxolitinib: Biology and clinical implications","volume":"106","author":"Ross","year":"2021","journal-title":"Haematologica"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood-2016-10-695965","article-title":"Emerging treatments for classical myeloproliferative neoplasms","volume":"129","author":"Vannucchi","year":"2017","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/jcmm.12202","article-title":"Combination therapies in Myeloproliferative Neoplasms: Why do we need them and how to identify potential winners?","volume":"17","author":"McLornan","year":"2013","journal-title":"J. Cell. Mol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-014-0095-z","article-title":"Pim kinases in hematological malignancies: Where are we now and where are we going?","volume":"7","author":"Mondello","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood-2014-06-579623","article-title":"p53 at the crossroads of MPN treatment","volume":"124","author":"Plo","year":"2014","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood-2018-08-872648","article-title":"CDK6 coordinates JAK2 (V617F) mutant MPN via NF-kappaB and apoptotic networks","volume":"133","author":"Uras","year":"2019","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1158\/0008-5472.CAN-21-0590","article-title":"CDK6 Is a Therapeutic Target in Myelofibrosis","volume":"81","author":"Dutta","year":"2021","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.3324\/haematol.2018.201921","article-title":"SDF1alpha-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K\/AKT, PLCgamma1 and RhoA","volume":"104","author":"Nimmagadda","year":"2019","journal-title":"Haematologica"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1158\/2159-8290.CD-11-0324","article-title":"Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent","volume":"2","author":"Andraos","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"eaat3834","DOI":"10.1126\/sciadv.aat3834","article-title":"Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis","volume":"4","author":"Tvorogov","year":"2018","journal-title":"Sci. Adv."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"115326","DOI":"10.1016\/j.bmc.2020.115326","article-title":"Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs","volume":"28","author":"Shah","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1021\/acsmedchemlett.1c00058","article-title":"Degradation of Janus Kinase for Potential Application in Immune Response Therapeutics","volume":"12","author":"Kargbo","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1182\/blood.2020006846","article-title":"Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia","volume":"138","author":"Chang","year":"2021","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Greenfield, G., McPherson, S., Smith, J., Mead, A., Harrison, C., Mills, K., and McMullin, M.F. (2020). Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms. Cancers, 12.","DOI":"10.3390\/cancers12092669"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/leu.2011.82","article-title":"DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms","volume":"25","author":"Pardanani","year":"2011","journal-title":"Leukemia"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2011.77","article-title":"DNMT3A mutations in myeloproliferative neoplasms","volume":"25","author":"Stegelmann","year":"2011","journal-title":"Leukemia"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/leu.2011.44","article-title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes","volume":"25","author":"Walter","year":"2011","journal-title":"Leukemia"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/jcmm.13095","article-title":"Epigenetics in Myeloproliferative Neoplasms","volume":"21","author":"McPherson","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: An international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.hoc.2020.11.003","article-title":"The Microenvironment in Myeloproliferative Neoplasms","volume":"35","author":"Ramanathan","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"100005","DOI":"10.1016\/j.cytox.2019.100005","article-title":"Cytokines frequently implicated in myeloproliferative neoplasms","volume":"1","author":"Wang","year":"2019","journal-title":"Cytokine X"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"683401","DOI":"10.3389\/fimmu.2021.683401","article-title":"Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms","volume":"12","author":"Fisher","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"102673","DOI":"10.1016\/j.dnarep.2019.102673","article-title":"Inflammation-induced DNA damage, mutations and cancer","volume":"83","author":"Kay","year":"2019","journal-title":"DNA Repair"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1155\/2015\/102476","article-title":"MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.humpath.2014.07.017","article-title":"Autoimmune myelofibrosis: An update on morphologic features in 29 cases and review of the literature","volume":"45","author":"Piatek","year":"2014","journal-title":"Hum. Pathol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Masselli, E., Pozzi, G., Gobbi, G., Merighi, S., Gessi, S., Vitale, M., and Carubbi, C. (2020). Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants. Cells, 9.","DOI":"10.3390\/cells9092136"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"598182","DOI":"10.3389\/fmed.2021.598182","article-title":"Cytokine Consistency Between Bone Marrow and Peripheral Blood in Patients With Philadelphia-Negative Myeloproliferative Neoplasms","volume":"8","author":"Chen","year":"2021","journal-title":"Front. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1182\/blood.V120.21.3805.3805","article-title":"The Molecular and Cytokine Profile of Triple-Negative (JAK2 V617F, JAK2 exon 12, MPL negative) Myelofibrosis, a Myeloproliferative Neoplasm with Distinct Clinico-Pathologic Characteristics","volume":"120","author":"Tabarroki","year":"2012","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","article-title":"Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFkappaB signaling","volume":"33","author":"Fisher","year":"2019","journal-title":"Leukemia"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"43974","DOI":"10.18632\/oncotarget.9949","article-title":"Crucial factors of the inflammatory microenvironment (IL-1beta\/TNF-alpha\/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: An in vitro study","volume":"7","author":"Sollazzo","year":"2016","journal-title":"Oncotarget"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/leu.2016.377","article-title":"Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia","volume":"31","author":"Fisher","year":"2017","journal-title":"Leukemia"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Hajmirza, A., Emadali, A., Gauthier, A., Casasnovas, O., Gressin, R., and Callanan, M.B. (2018). BET Family Protein BRD4: An Emerging Actor in NFkappaB Signaling in Inflammation and Cancer. Biomedicines, 6.","DOI":"10.3390\/biomedicines6010016"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.molcel.2018.06.036","article-title":"DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4","volume":"71","author":"Jin","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem. Biol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/leu.2016.393","article-title":"Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary(s) AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/blood.V96.6.2022","article-title":"Transforming growth factor-beta: Pleiotropic role in the regulation of hematopoiesis","volume":"96","author":"Fortunel","year":"2000","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","article-title":"Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice","volume":"100","author":"Chagraoui","year":"2002","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.exphem.2006.08.016","article-title":"Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development","volume":"35","author":"Gastinne","year":"2007","journal-title":"Exp. Hematol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Varricchio, L., Iancu-Rubin, C., Upadhyaya, B., Zingariello, M., Martelli, F., Verachi, P., Clementelli, C., Denis, J.F., Rahman, A.H., and Tremblay, G. (2021). TGF-beta1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. JCI Insight, 6.","DOI":"10.1172\/jci.insight.145651"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm.3706","article-title":"Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells","volume":"20","author":"Zhao","year":"2014","journal-title":"Nat. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e2018068","DOI":"10.4084\/mjhid.2018.068","article-title":"Megakaryocyte Contribution to Bone Marrow Fibrosis: Many Arrows in the Quiver","volume":"10","author":"Malara","year":"2018","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1182\/blood-2015-07-607952","article-title":"Genomic landscape of megakaryopoiesis and platelet function defects","volume":"127","author":"Bianchi","year":"2016","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.ajpath.2017.03.009","article-title":"Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations","volume":"187","author":"Guo","year":"2017","journal-title":"Am. J. Pathol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/nm.3995","article-title":"Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition","volume":"21","author":"Wen","year":"2015","journal-title":"Nat. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1158\/1078-0432.CCR-19-1481","article-title":"Aurora Kinase A Inhibition: A Mega-Hit for Myelofibrosis Therapy?","volume":"25","author":"Piszczatowski","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2016.12.007","article-title":"Kinase signaling and targeted therapy for primary myelofibrosis","volume":"48","author":"Yang","year":"2017","journal-title":"Exp. Hematol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjh.12709","article-title":"Rho kinase inhibition drives megakaryocyte polyploidization and proplatelet formation through MYC and NFE2 downregulation","volume":"164","author":"Avanzi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1182\/blood-2008-03-144956","article-title":"Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho\/Rock signaling","volume":"112","author":"Lordier","year":"2008","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ccr.2011.07.016","article-title":"Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL","volume":"20","author":"Mali","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MOH.0000000000000056","article-title":"Role of Rho kinases in abnormal and normal hematopoiesis","volume":"21","author":"Mali","year":"2014","journal-title":"Curr. Opin. Hematol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/sj.leu.2404762","article-title":"The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells","volume":"21","author":"Burthem","year":"2007","journal-title":"Leukemia"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1182\/blood-2014-05-575001","article-title":"Morgana acts as an oncosuppressor in chronic myeloid leukemia","volume":"125","author":"Panuzzo","year":"2015","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-018-0774-4","article-title":"Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia","volume":"17","author":"Rocca","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nm.2079","article-title":"The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure","volume":"16","author":"Guilluy","year":"2010","journal-title":"Nat. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"32737","DOI":"10.1074\/jbc.M400601200","article-title":"RhoA\/ROCK activation by growth hormone abrogates p300\/histone deacetylase 6 repression of Stat5-mediated transcription","volume":"279","author":"Ling","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/nn.3207","article-title":"Rho-kinase regulates energy balance by targeting hypothalamic leptin receptor signaling","volume":"15","author":"Huang","year":"2012","journal-title":"Nat. Neurosci."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e24074","DOI":"10.4161\/jkst.24074","article-title":"ROCKing the JAKs","volume":"2","author":"Peelman","year":"2013","journal-title":"Jak-Stat"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"16636","DOI":"10.1038\/s41598-018-35109-9","article-title":"ROCK2, but not ROCK1 interacts with phosphorylated STAT3 and co-occupies TH17\/TFH gene promoters in TH17-activated human T cells","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1158\/1078-0432.CCR-11-1541","article-title":"Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells","volume":"17","author":"Fiskus","year":"2011","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1172\/JCI42442","article-title":"HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans","volume":"120","author":"Marubayashi","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1158\/1078-0432.CCR-13-0905","article-title":"JAK1\/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease","volume":"19","author":"Evrot","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1158\/1078-0432.CCR-20-4898","article-title":"Therapeutic Efficacy of Combined JAK1\/2, Pan-PIM, and CDK4\/6 Inhibition in Myeloproliferative Neoplasms","volume":"27","author":"Rampal","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1038\/s41375-021-01391-2","article-title":"Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy","volume":"35","author":"Brkic","year":"2021","journal-title":"Leukemia"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12943-015-0388-z","article-title":"Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms","volume":"14","author":"Pandey","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2011-01-330563","article-title":"Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"40141","DOI":"10.18632\/oncotarget.5653","article-title":"The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells","volume":"6","author":"Mazzacurati","year":"2015","journal-title":"Oncotarget"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"CT162","DOI":"10.1158\/1538-7445.AM2021-CT162","article-title":"Abstract CT162: Addition of parsaclisib (INCB050465), a PI3K\u03b4 inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis","volume":"81","author":"Yacoub","year":"2021","journal-title":"Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"LBA1","DOI":"10.1200\/JCO.2021.39.15_suppl.LBA1","article-title":"OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1\/2 mutations and high-risk HER2-negative early breast cancer","volume":"39","author":"Tutt","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/jcmm.12156","article-title":"Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors","volume":"17","author":"Choong","year":"2013","journal-title":"J. Cell. Mol. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1080\/10428190802527699","article-title":"Enhanced histone deacetylase enzyme activity in primary myelofibrosis","volume":"49","author":"Wang","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10428194.2011.597905","article-title":"Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms","volume":"53","author":"Skov","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1080\/13543784.2016.1250882","article-title":"Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms","volume":"25","author":"Bose","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.leu.2405049","article-title":"The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)","volume":"22","author":"Guerini","year":"2008","journal-title":"Leukemia"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.exphem.2012.04.007","article-title":"The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells","volume":"40","author":"Todoerti","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1182\/blood-2011-02-336743","article-title":"Efficacy of vorinostat in a murine model of polycythemia vera","volume":"119","author":"Akada","year":"2012","journal-title":"Blood"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1158\/2159-8290.CD-20-0026","article-title":"PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2(V617F)-Mutant MPN","volume":"10","author":"Pastore","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1128\/MCB.01365-08","article-title":"Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA","volume":"29","author":"Huang","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1042\/BCJ20210139","article-title":"Inhibitory feedback control of NF-kappaB signalling in health and disease","volume":"478","author":"Prescott","year":"2021","journal-title":"Biochem. J."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.4049\/jimmunol.1900321","article-title":"Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes","volume":"203","author":"Hofland","year":"2019","journal-title":"J. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pilie","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1182\/blood-2017-05-784942","article-title":"Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms","volume":"130","author":"Maifrede","year":"2017","journal-title":"Blood"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-020-2968-3","article-title":"Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms","volume":"588","author":"Jayavelu","year":"2020","journal-title":"Nature"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2013-11-536854","article-title":"The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon alpha 2a target JAK2V617F-positive progenitor and stem cells","volume":"124","author":"Lu","year":"2014","journal-title":"Blood"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13045-020-00995-y","article-title":"Novel therapeutics in myeloproliferative neoplasms","volume":"13","author":"Venugopal","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/blood-2021-147543","article-title":"Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed\/Refractory Myelofibrosis (MF)","volume":"138","author":"Vachani","year":"2021","journal-title":"Blood"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups","volume":"32","author":"Bolli","year":"2018","journal-title":"Leukemia"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: Underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Pinto, V., Bergantim, R., Caires, H.R., Seca, H., Guimaraes, J.E., and Vasconcelos, M.H. (2020). Multiple Myeloma: Available Therapies and Causes of Drug Resistance. Cancers, 12.","DOI":"10.3390\/cancers12020407"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12935-021-01746-w","article-title":"Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: Towards precision medicine overcoming drug resistance","volume":"21","author":"Levin","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_183","first-page":"190","article-title":"Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML)","volume":"49","author":"Cianfriglia","year":"2013","journal-title":"Ann. Ist. Super. Sanita"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/972\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:20:12Z","timestamp":1760134812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":183,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14040972"],"URL":"https:\/\/doi.org\/10.3390\/cancers14040972","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,2,15]]}}}